Drug Trial Radar · NCT02582736
Antipsychotics and Risk of Hyperglycemic Emergencies
Last checked: Nov 19, 2026Latest source record: Oct 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
725,489
Actual
Start
Apr 2012
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Canadian Network for Observational Drug Effect Studies, CNODESAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Drug Safety and Effectiveness Network, Canada; Canadian Institutes of Health Research (CIHR)
- First posted
- Oct 21, 2015
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
Conditions
- Psychotic Disorders
- Schizophrenia
- Schizoaffective Disorder
- Bipolar Disorder
- Diabetes Mellitus, Type 2
Interventions
OlanzapineDrug
Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
RisperidoneDrug
Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
atypical antipsychotics (other)Drug
Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
typical antipsychoticsDrug
Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospitalization for a hyperglycemic emergencyTime frame: Patients will be followed from the date of study cohort entry until the occurrence of a hyperglycemic emergency, censoring, or for up to 365 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Women's College Hospital, Women's College Research Institute
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.